Annexon Biosciences Inc.

https://www.annexonbio.com

Annexon Biosciences is creating and developing proprietary therapeutic products that modulate the classical complement pathway. Our pipeline is based on breakthrough research showing that the initiating molecule of the classical pathway, C1q, stimulates an immune-mediated attack that causes cell loss and tissue damage in a broad array of autoimmune, neurodegenerative and ophthalmic disorders. *

	Start	2011-01-01 established
	End	2020-07-01 renamed before?
	Group	Annexon Inc. (ANNX)
	Industry	BIOTECH
	Person	Love, Douglas (Doug) (Annexon Biosciences 201812 CEO)

	Street	180 Kimball Way 2nd Floor, Suite 200
	City	94080 South San Francisco, CA
	Tel	+1-650-822-5500
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: Annexon Biosciences Inc.. (12/19/18). "Press Release: Annexon Biosciences Closes $75 Million Financing". South San Francisco, CA.

		Record changed: 2023-07-10

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Annexon Inc. (ANNX)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)